AU2005294146B2 - Modulators of hepatocyte growth factor activator - Google Patents

Modulators of hepatocyte growth factor activator Download PDF

Info

Publication number
AU2005294146B2
AU2005294146B2 AU2005294146A AU2005294146A AU2005294146B2 AU 2005294146 B2 AU2005294146 B2 AU 2005294146B2 AU 2005294146 A AU2005294146 A AU 2005294146A AU 2005294146 A AU2005294146 A AU 2005294146A AU 2005294146 B2 AU2005294146 B2 AU 2005294146B2
Authority
AU
Australia
Prior art keywords
antibody
seq
hgfa
sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005294146A
Other languages
English (en)
Other versions
AU2005294146A1 (en
Inventor
Daniel K. Kirchhofer
Yan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2005294146A1 publication Critical patent/AU2005294146A1/en
Application granted granted Critical
Publication of AU2005294146B2 publication Critical patent/AU2005294146B2/en
Priority to AU2011254032A priority Critical patent/AU2011254032B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2005294146A 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator Ceased AU2005294146B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011254032A AU2011254032B2 (en) 2004-10-04 2011-12-14 Modulators of Hepatocyte Growth Factor Activator

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
US60/615,657 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011254032A Division AU2011254032B2 (en) 2004-10-04 2011-12-14 Modulators of Hepatocyte Growth Factor Activator

Publications (2)

Publication Number Publication Date
AU2005294146A1 AU2005294146A1 (en) 2006-04-20
AU2005294146B2 true AU2005294146B2 (en) 2011-09-15

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005294146A Ceased AU2005294146B2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Country Status (15)

Country Link
US (4) US20060147451A1 (OSRAM)
EP (1) EP1809673B1 (OSRAM)
JP (2) JP4937127B2 (OSRAM)
KR (1) KR101252306B1 (OSRAM)
CN (1) CN101035810B (OSRAM)
AU (1) AU2005294146B2 (OSRAM)
BR (1) BRPI0515670A (OSRAM)
CA (1) CA2577598C (OSRAM)
ES (1) ES2398528T3 (OSRAM)
IL (1) IL181450A0 (OSRAM)
NO (1) NO20072302L (OSRAM)
NZ (1) NZ553327A (OSRAM)
RU (1) RU2418004C2 (OSRAM)
WO (1) WO2006042173A2 (OSRAM)
ZA (1) ZA200701789B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
CN101652389A (zh) * 2007-02-09 2010-02-17 健泰科生物技术公司 抗robo4抗体及其用途
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466593A (en) * 1992-11-05 1995-11-14 Mitsubishi Kasei Corporation Hepatocyte growth factor activating protease and gene encoding the protease
EP1213302A1 (en) * 2000-12-05 2002-06-12 Mitsubishi Chemical Corporation Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466593A (en) * 1992-11-05 1995-11-14 Mitsubishi Kasei Corporation Hepatocyte growth factor activating protease and gene encoding the protease
EP1213302A1 (en) * 2000-12-05 2002-06-12 Mitsubishi Chemical Corporation Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KATAOKA, H. et al., Cancer Research. 2000, vol. 60, pages 6148-6159 *
MIYAZAWA, K. et al., Journal of Biological Chemistry, 1996, vol. 271, pages 3615-3618 *
SHIMOMURA, T. et al., European Journal of Biochemistry. 1995, vol. 229, pages 257-261 *

Also Published As

Publication number Publication date
EP1809673A2 (en) 2007-07-25
KR101252306B1 (ko) 2013-04-08
EP1809673B1 (en) 2012-11-28
IL181450A0 (en) 2007-07-04
US20090047291A1 (en) 2009-02-19
JP2012025752A (ja) 2012-02-09
KR20070102470A (ko) 2007-10-18
US20110098449A1 (en) 2011-04-28
US7825221B2 (en) 2010-11-02
US20130217862A1 (en) 2013-08-22
CA2577598C (en) 2016-09-20
JP4937127B2 (ja) 2012-05-23
CN101035810A (zh) 2007-09-12
CA2577598A1 (en) 2006-04-20
NO20072302L (no) 2007-06-28
NZ553327A (en) 2010-02-26
HK1105006A1 (en) 2008-02-01
CN101035810B (zh) 2011-04-06
JP2008515918A (ja) 2008-05-15
US8969528B2 (en) 2015-03-03
AU2005294146A1 (en) 2006-04-20
RU2007116806A (ru) 2008-11-10
ES2398528T3 (es) 2013-03-19
JP5554298B2 (ja) 2014-07-23
BRPI0515670A (pt) 2008-07-29
WO2006042173A3 (en) 2006-08-17
WO2006042173A2 (en) 2006-04-20
US8399629B2 (en) 2013-03-19
US20060147451A1 (en) 2006-07-06
RU2418004C2 (ru) 2011-05-10
ZA200701789B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
US8399629B2 (en) Antibody modulators of hepatocyte growth factor activator
CA2577678C (en) Humanized anti-beta7 integrin subunit antibodies and uses therefor
AU2005267720B2 (en) Humanized anti-cmet antagonists
CA2638133A1 (en) Anti-ephrinb2 antibodies and methods using same
US8759491B2 (en) Modulators of hepatocyte growth factor activator
AU2011254032B2 (en) Modulators of Hepatocyte Growth Factor Activator
AU2012202209A1 (en) Humanized anti-cmet antagonists
MX2007003832A (en) Modulators of hepatocyte growth factor activator
HK1105006B (en) Modulators of hepatocyte growth factor activator

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired